Longitudinal studies incorporating objective biomarkers (e.g., inflammatory cytokines, gut microbiota profiles), standardised cognitive assessments, and robust measures of nutritional status are particularly needed
Monograph for "Talc", Handbook of Pharmaceutical Excipients, Second Edition, American Pharmaceutical Association, 1994, pp: 519-521
The only FDA-approved form of bremelanotide is Vyleesi, which is a subcutaneous injection
In Study A, women receiving PT-141 three times daily for 15 days exhibited significantly greater body weight reduction compared to placebo (1.3 kg difference) with high statistical significance
Sun et al., 2025
doi: 10.2337/diabetes.55.01.06.db05-0751